β-Cell–Mediated Signaling Predominates Over Direct α-Cell Signaling in the Regulation of Glucagon Secretion in Humans by Cooperberg, Benjamin A. & Cryer, Philip E.
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Regulation of Glucagon Secretion in
Humans
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OBJECTIVE — Givenevidenceofbothindirectanddirectsignaling,wetestedthehypothesis
that increased -cell–mediated signaling of -cells negates direct -cell signaling in the regula-
tion of glucagon secretion in humans.
RESEARCH DESIGN AND METHODS — We measured plasma glucagon concentra-
tions before and after ingestion of a formula mixed meal and, on a separate occasion, ingestion
of the sulfonylurea glimepiride in 24 basal insulin-infused, demonstrably -cell–deﬁcient pa-
tients with type 1 diabetes and 20 nondiabetic, demonstrably -cell–sufﬁcient individuals; the
latter were infused with glucose to prevent hypoglycemia after glimepiride.
RESULTS — After the mixed meal, plasma glucagon concentrations increased from 22  1
pmol/l(784pg/ml)to302pmol/l(1037pg/ml)inthepatientswithtype1diabetesbut
were unchanged from 27  1 pmol/l (93  3 pg/ml) to 26  1 pmol/l (89  3 pg/ml) in the
nondiabetic individuals (P  0.0001). After glimepiride, plasma glucagon concentrations in-
creasedfrom241pmol/l(834pg/ml)to261pmol/l(914pg/ml)inthepatientswith
type 1 diabetes and decreased from 28  1 pmol/l (97  5 pg/ml) to 24  1 pmol/l (82  4
pg/ml) in the nondiabetic individuals (P  0.0001). Thus, in the presence of both -cell and
-cell secretory stimuli (increased amino acid and glucose levels, a sulfonylurea) glucagon
secretion was prevented when -cell secretion was sufﬁcient but not when -cell secretion was
deﬁcient.
CONCLUSIONS — These data indicate that, among the array of signals, indirect reciprocal
-cell–mediatedsignalingpredominatesoverdirect-cellsignalingintheregulationofglucagon
secretion in humans.
Diabetes Care 32:2275–2280, 2009
T
he regulation of pancreatic islet
-cell glucagon secretion is com-
plex (1–10). It involves direct sig-
naling of -cells (1) and indirect
signaling of -cells by -cell (2–6) and
-cell (7) secretory products, the auto-
nomic nervous system (8,9), and gut
incretins (10).
Appropriate glucagon secretory re-
sponsesoccurfromtheperfusedpancreas
(3,5) and perifused islets (2). Low plasma
glucose concentrations stimulate gluca-
gon secretion from the transplanted (i.e.,
denervated)humanpancreas(11)andthe
denervated dog pancreas (12). Therefore,
we have focused on the intraislet regula-
tion of glucagon secretion. Furthermore,
becauseselectivedestructionof-cellsre-
sults in loss of the glucagon response to
hypoglycemiaintype1diabetes(13),and
partial reduction of the -cell mass in
minipigs results in impaired postprandial
suppression of glucagon secretion (14),
we have focused on the role of -cell–
mediated signaling in the regulation of
glucagon secretion.
Findings from studies of the perfused
rat (3,4) and human (5) pancreas, rats in
vivo (6), rat islets (2), isolated rat -cells
(2),andhumans(15–18)havebeeninter-
preted to indicate that a -cell secretory
product or products tonically restrains
basal-cellglucagonsecretionduringeu-
glycemia and that a decrease in -cell se-
cretion, coupled with low glucose
concentrations at the -cells, signals an
increaseinglucagonsecretioninresponse
to hypoglycemia. Parenthetically, the
relativerolesofthecandidate-cellsecre-
tory products (insulin, zinc, -aminobu-
tyric acid, and amylin, among others) (2)
that normally restrain -cell glucagon se-
cretion remain to be determined. How-
ever, that interpretation rests, in part, on
resultsofstudiesinisolatedrat-cells(2),
which are debated (1), and on the evi-
dencethattheisletmicrocirculationﬂows
from -cells to -cells to -cells (4),
which is also debated (19). Furthermore,
it does not address the plausible possibil-
ity that a decrease in intraislet -cell so-
matostatin secretion might also signal an
increase in -cell glucagon secretion dur-
ing hypoglycemia (7).
Given that interpretation, it follows
that an increase in -cell secretion would
signal a decrease in glucagon secretion in
thepostprandialstate(14).Theconceptis
an interplay of indirect reciprocal -cell–
mediatedsignalingof-cellsandofdirect
-cellsignalingintheregulationofgluca-
gon secretion.
There is, in our view, compelling ev-
idence that, among other mechanisms,
both indirect reciprocal -cell–mediated
signaling of -cells (2–6) and direct
-cell signaling (1) are involved in the
regulation of glucagon secretion by nutri-
ents, hormones, neurotransmitters, and
drugs. Given that premise, we posed the
question:Whichofthesepredominatesin
humans? Accordingly, we tested the hy-
pothesis that increased -cell–mediated
signaling of -cells negates direct -cell
signaling in the regulation of glucagon se-
cretion in humans. To do so, we mea-
sured plasma glucagon responses to
ingestion of a mixed meal and, on a sep-
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nylurea glimepiride in patients with type
1diabetesandinnondiabeticindividuals.
We conceptualized patients with type 1
diabetes as a model of -cells isolated
from -cells because their -cells had
been destroyed but they have functioning
-cells. (Their -cells are not, of course,
isolated from other islet cells, including
-cells.)Increasedplasmaaminoacidand
glucose levels after a mixed meal and sul-
fonylureas normally stimulate -cell se-
cretion; increased plasma amino acid and
perhaps glucose (2) levels after a mixed
meal and sulfonylureas (1) stimulate
-cell secretion. Our hypothesis predicts
that such factors that normally stimulate
both -cells and -cells would stimulate
glucagon secretion in patients with type 1
diabetes but not in nondiabetic individu-
als, i.e., in the virtual absence and the
presence of -cell function, respectively.
Indeed, a mixed meal (20,21) and the
secretagogues tolbutamide (22), gly-
buride (23), and repaglinide (23) have
been reported to raise plasma glucagon
concentrations in patients with type 1 di-
abetes,butallofthosestudieslackednon-
diabetic control subjects.
RESEARCH DESIGN AND
METHODS— Twenty-four patients
with type 1 diabetes (9 women) and 20
nondiabeticindividuals(10women)gave
their written consent to participate in this
study, which was approved by the Wash-
ington University Human Research Pro-
tection Ofﬁce and conducted at the
university’sClinicalResearchUnit(CRU).
Their mean  SD ages were 25.9  9.5
and 27.0  3.2 years, BMIs were 26.2 
3.8and24.65.0kg/m
2,andA1Clevels
were 7.5  1.1 and 5.3  0.3%, respec-
tively.Thedurationoftype1diabeteswas
11.8  8.2 years. Twelve of the patients
were using a continuous subcutaneous
insulin infusion regimen with a rapid-
actinginsulinanalog,and12wereusinga
multiple daily injection insulin regimen
with glargine as the basal insulin in 10
and NPH as the basal insulin in 2 with
rapid-acting analogs as the prandial
insulin.
Thepatientswithtype1diabetestook
their last dose of long-acting insulin (if
used) 24 h before the study. They used a
rapid-acting insulin to control their dia-
betesuntiltheywereadmittedtotheCRU
the evening before study. Regular human
insulin (Novolin R; Novo Nordisk,
Princeton, NJ) was infused intravenously
to maintain near-euglycemia (5.6
mmol/l [100 mg/dl]) overnight. After an
overnight fast, an arterialized venous
sampling line was inserted into a hand
vein (with that hand kept in an 55°C
Plexiglas box), and the insulin infusion
was adjusted to maintain stable euglyce-
mia; that insulin infusion dose was then
continued through the end of the study.
Nondiabetic individuals presented to the
CRU,afteranovernightfast,onthedayof
study.
Both study groups ingested a formula
mixed meal (Ensure Plus; 355 kcal, 50 g
carbohydrate, 13 g protein, and 11 g fat)
on one study occasion and 4.0 mg
glimepiride (Amaryl; sanoﬁ-aventis U.S.,
Bridgewater, NJ) on the other study occa-
sion. Glucose was infused intravenously
to maintain euglycemia after glimepiride
ingestion in the nondiabetic individuals.
Blood samples were drawn every 15 min-
utes. Heart rates and blood pressures
(Propaq Encore; Protocol Systems, Bea-
verton, OR) were measured throughout.
Analytical methods
Plasma glucose was measured with a glu-
cose oxidase method (YSI Glucose Ana-
lyzer; YSI, Yellow Springs, OH). Plasma
insulin, C-peptide, cortisol, and growth
hormone were measured with solid-
phase, two-site chemiluminescent immu-
nometric assays (Immulite 1000;
Siemens, Los Angeles, CA); plasma gluca-
gon and pancreatic polypeptide were
measuredwithLincoradioimmunoassays
(Millipore, Temecula, CA). Plasma epi-
nephrine and norepinephrine were mea-
sured with a single isotope derivative
(radioenzymatic) method, and blood lac-
tate and serum nonesteriﬁed fatty acids
were measured with enzymatic
techniques.
Statistical methods
Time and condition-related variables
were analyzed by repeated-measures
mixed-modelANOVA.Contrastsofinter-
est were compared with Student’s t test.
P  0.05 was considered to indicate sig-
niﬁcant differences.
RESULTS
Fasting plasma glucose and glucagon
concentrations
Fasting plasma glucagon concentrations
were similar in the two groups when they
were sampled, after an overnight fast, at
the screening visits but were lower (P 
0.0007 and 0.0278) in the patients with
type 1 diabetes after intravenous insulin
infusion to maintain near-euglycemia
overnight (Table 1).
Plasma glucose, C-peptide, insulin,
and epinephrine
In the patients with type 1 diabetes,
plasma C-peptide concentrations re-
mained low, plasma insulin concentra-
tions were constant, and plasma glucose
concentrations increased from 5.6  0.2
mmol/l (101  3 mg/dl) to a peak of
14.30.6mmol/l(25711mg/dl)after
ingestion of the mixed meal (Fig. 1). In
the nondiabetic individuals, plasma glu-
coseconcentrationsincreasedfrom4.9
0.0 mmol/l (88  1 mg/dl) to a peak of
6.6  0.2 mmol/l (118  3 mg/dl) at 30
min,plasmaC-peptideconcentrationsin-
creased from 0.5  0.9 nmol/l (1.4  0.1
n g / m l )t oap e a ko f1 . 6 0.1 nmol/l
(5.0  0.4 ng/ml) at 45 min, and plasma
insulin concentrations increased from
36  6 pmol/l (6  1 	U/ml) to a peak of
264  30 pmol/l (44  5 	U/ml) at 30
min (Fig. 1). The plasma glucose, C-
peptide, and insulin levels differed be-
tween the patients and control subjects
(all P  0.0001). Plasma epinephrine
concentrations were low and similar
(Fig. 1).
In the patients with type 1 diabetes,
plasma C-peptide concentrations re-
mained low, plasma insulin concentra-
tions were constant, and plasma glucose
concentrations increased gradually from
Table 1—Fasting plasma glucose and gluca-
gon concentrations in patients with type 1 di-
abetes and nondiabetic individuals sampled
at the screening visit and at 0 min in the
mixed meal and glimepiride studies after in-
travenous insulin infusion to maintain near-
euglycemia overnight in the patients with
type 1 diabetes
Type 1
diabetes Nondiabetic
n 24 20
Plasma glucose
(mmol/l)
Screening 7.7  0.7 4.7  0.1
Mixed-meal study 5.6  0.2 4.9  0.1
Glimepiride study 6.0  0.2 4.9  0.1
Plasma glucagon
(pmol/l)
Screening 27  12 7  1
Mixed-meal study 22  1* 27  1
Glimepiride study 24  1† 28  1
DataaremeansSEM.Toconvertglucosetomg/dl
divide by 0.05551, glucagon to pg/ml divide by
0.2871. *P  0.0007. †P  0.0278.
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peak of 9.4  0.9 mmol/l (169  17 mg/
dl) at 225 min after ingestion of
glimepiride (Fig. 2). In the nondiabetic
individuals, glucose was infused to pre-
vent hypoglycemia (the lowest mean
plasma glucose concentration was 4.6 
0.9 mmol/l [84  1 mg/dl] at 165 min),
plasma C-peptide concentrations in-
creased from 0.5  0.9 nmol/l (1.4  0.1
ng/ml) to a peak of 1.3  0.2 nmol/l
(3.80.6ng/ml)at210min,andplasma
insulin concentrations increased from
36  6 pmol/l (6  1 	U/ml) to a peak
of 138  24 pmol/l (23  4 	U/ml) at
195 min (Fig. 2). The plasma glucose,
C-peptide, and insulin levels differed
between the patients and the control
subjects (all P  0.0001). Plasma epi-
nephrine concentrations were low and
similar (Fig. 2).
Plasma glucagon
In the patients with type 1 diabetes,
plasma glucagon concentrations in-
creased from 22  1 pmol/l (78  4 pg/
ml) to a peak of 30  2 pmol/l (103  7
pg/ml) at 30 min after ingestion of the
mixed meal and from 24  1 pmol/l
(834pg/ml)toapeakof261pmol/l
(91  4 pg/ml) at 135 min after ingestion
of glimepiride (Fig. 3). In the nondiabetic
individuals, plasma glucagon concentra-
tions tended to decline from 27  1
pmol/l (93  3 pg/ml) to 26  1 pmol/l
(89  3 pg/ml) at 105 min after ingestion
of the mixed meal and decreased from
281pmol/l(975pg/ml)toanadirof
24  1 pmol/l (82  4 pg/ml) at 195 min
afteringestionofglimepiride(Fig.3).The
baseline-adjusted plasma glucagon levels
differed between the patients and control
subjects (both P  0.0001).
Other neuroendocrine and metabolic
parameters
Plasma norepinephrine concentrations
wereunchangedafterthemixedmealand
glimepiride and did not differ between
the groups (data not shown). After the
mixed meal, plasma pancreatic polypep-
tide concentrations increased from 25 
4 pmol/l (105  17 pg/ml) to a peak of
59  9 pmol/l (246  39 pg/ml) at 30
min in the patients with type 1 diabetes
andfrom293pmol/l(12314pg/ml)
to a peak of 67  9 pmol/l (279  36
pg/ml) at 15 min in the nondiabetic indi-
viduals; they were unchanged after
glimepiride.Pancreaticpolypeptidelevels
did not differ between the patients and
control subjects. Plasma cortisol and
growth hormone concentrations also did
not differ between the patients and con-
trol subjects under either condition (data
not shown).
After ingestion of the mixed meal,
blood lactate concentrations increased
from 784  93 to 1,071  160 	mol/l at
120 min in the patients with type 1 dia-
betes and from 660  56 to 1,590  127
	mol/l at 75 min in the nondiabetic indi-
viduals (P  0.0221). Lactate levels were
unchanged and similar in both groups af-
ter ingestion of glimepiride. Serum non-
esteriﬁed fatty acid concentrations were
unaltered in the patients after the mixed
meal and glimepiride but were sup-
Figure 1—Means  SEM plasma glucose, C-peptide, insulin, and epinephrine concentrations
before and after ingestion of a mixed meal in basal insulin–infused patients with type 1 diabetes
(T1DM)(F)andnondiabetic(ND)individuals(E).Differencesinglucose,C-peptide,andinsulin
levels, P  0.0001.
Figure 2—Means  SEM plasma glucose, C-peptide, insulin, and epinephrine concentrations
before and after ingestion of the sulfonylurea glimepiride in basal insulin–infused patients with
type1diabetes(T1DM)(F)andnondiabetic(ND)individuals(E),thelatterinfusedwithglucose
intravenously to prevent hypoglycemia. Differences in insulin, C-peptide, and insulin levels, P 
0.0001.
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	mol/l at 75 min and from 786  92 to
310 	mol/l at 195 min, respectively, un-
der the two conditions in the control sub-
jects (both P  0.0001).
CONCLUSIONS — We tested the
hypothesis that increased -cell–
mediated signaling of -cells negates di-
rect -cell signaling in the regulation of
glucagon secretion in humans. To do so,
we contrasted the plasma glucagon re-
sponses to the ingestion of a mixed meal
and sulfonylurea glimepiride, conditions
that normally stimulate both -cells and
-cells, in nondiabetic individuals and
patients with type 1 diabetes, i.e., in indi-
viduals with normal and virtually absent
-cell function, respectively. The data
support our hypothesis. Plasma glucagon
concentrations were unchanged or de-
creased in the nondiabetic individuals
with intact -cell function but were in-
creased in the patients with -cell failure
afteringestionofboththemixedmealand
glimepiride.
We attribute these dichotomous
plasmaglucagonconcentrationresponses
to the presence and virtual absence of
-cell function in the nondiabetic indi-
viduals and the patients with type 1 dia-
betes, respectively. It is likely that that
was not the only difference between the
two groups. For example, appropriate
provocative testing would most likely
have demonstrated reduced autonomic
(adrenomedullary, sympathetic, and
parasympathetic) responses in the pa-
tientswithtype1diabetes(24).However,
reduced autonomic responses, which are
allnormallystimulatory(8),couldnotex-
plain the observed increased glucagon re-
sponses (8,9). In the present study,
plasma epinephrine and norepinephrine
concentrations (measures of sympathoa-
drenal activity) and plasma pancreatic
polypeptide concentrations (a measure of
parasympathetic activity) were compara-
bleinbothgroupsunderbothconditions.
Therefore, differences in autonomic sig-
nalingcouldnotexplaintheobserveddif-
ferences in the glucagon responses.
Among the gut incretins, glucagon-like
peptide-1 (GLP-1), but not glucose-
dependent insulinotropic polypeptide
(GIP), normally suppresses glucagon se-
cretion (10). Thus, reduced GLP-1, but
not GIP, actions in patients with diabetes
could explain less suppression of gluca-
gon secretion after a mixed meal. How-
ever, that suppression would not explain
the observed increased glucagon re-
sponses to a mixed meal or those to
glimepirideinthepatients.Thus,wecon-
cludethatourdataareconsistentwiththe
interpretation that indirect reciprocal
-cell–mediated signaling predominates
over direct -cell signaling in the regula-
tion of glucagon secretion in humans.
That conclusion does not exclude an ad-
ditional role for -cell somatostatin.
The relative contributions of the po-
tential -cell secretory products that nor-
mally restrain -cell glucagon secretion
(2) remain to be clariﬁed. That issue is of
considerable biological interest. How-
ever, the identity of the relevant -cell se-
cretory products is not critical to the
interpretation of our evidence that indi-
rectreciprocal-cell–mediatedsignaling,
whatever the signaling molecules, pre-
dominates over direct -cell signaling in
the regulation of glucagon secretion.
The signiﬁcantly lower baseline
plasma glucagon concentrations in the
patients with type 1 diabetes on both the
mixed-mealandtheglimepiridestudyoc-
casions were most likely the result of the
intravenous insulin infusions used to
maintain near-euglycemia overnight.
Fasting plasma glucagon concentrations
were similar in the patients with type 1
diabetes and in the nondiabetic individu-
als sampled after an overnight fast in the
absence of overnight insulin infusion in
thepatients.Theseﬁndingsdocumentthe
fact that replacement doses of exogenous
insulin or one of the components of the
insulinpreparationsuppressglucagonse-
cretion. Notably, however, the lower
baseline plasma glucagon concentrations
did not preclude the ﬁnding of an en-
hanced glucagon response to both
stimuli.
The-cellactionsofsulfonylureasare
complex. For example, low concentra-
tions of tolbutamide stimulate glucagon
release from mouse islets, whereas high
concentrations are inhibitory (1). In hu-
mans, intravenous tolbutamide, which
stimulated -cell secretion, neither raised
nor lowered basal plasma glucagon con-
centrations (15,17) but prevented the
glucagon response to hypoglycemia (15).
In the present study, the sulfonylurea
glimepiride raised plasma glucagon con-
centrationsinthevirtualabsenceof-cell
function, implying a direct -cell stimu-
latory effect.
This study was not designed to assess
the impact of glucagon on glycemia in
type 1 diabetes. Plasma glucose concen-
trations increased substantially after in-
gestion of the mixed meal in the patients
with type 1 diabetes. That result is plau-
sibly attributable to the absence of an in-
crease in insulin secretion; an additional
effect of the documented increase in glu-
cagon secretion cannot be excluded.
Plasma glucose concentrations rose after
Figure 3—Means  SEM plasma glucagon concentrations (left panels) and change in plasma
glucagon from zero time (right panels) before and after ingestion of a mixed meal (top panels)
and of the sulfonylurea glimepiride (bottom panels) in basal insulin–infused patients with type 1
diabetes (T1DM) (F) and nondiabetic (ND) individuals (E). Differences in baseline-adjusted
glucagon levels, P  0.0001.
Glucagon secretion
2278 DIABETES CARE, VOLUME 32, NUMBER 12, DECEMBER 2009 care.diabetesjournals.orgingestion of glimepiride in the patients
with type 1 diabetes despite ongoing in-
sulin infusion. Although it is conceiv-
able that the documented increase in
glucagon secretion contributed to that
increase in plasma glucose, the tempo-
ral pattern suggests that an additional,
unidentiﬁed factor was involved. The
possibility of imperfect insulin replace-
ment remains.
The ﬁnding of predominant -cell
regulation of -cell glucagon secretion
has clinical implications. Given that a de-
crease in an intraislet -cell secretory
product, in concert with low -cell glu-
cose concentrations, normally signals an
increase in -cell glucagon secretion dur-
inghypoglycemia(15–18),itfollowsthat,
because it stems fundamentally from
-cell failure, the pathophysiology of glu-
cosecounterregulationisthesameintype
1 diabetes and advanced type 2 diabetes,
albeit with different time courses (24): in
the setting of a period of therapeutic hy-
perinsulinemia and the resulting falling
plasma glucose concentrations, -cell
failurecausesneitheradecreaseininsulin
secretion nor an increase in glucagon se-
cretion leading to an episode of hypogly-
cemia; the latter causes an attenuated
sympathoadrenal response to subsequent
hypoglycemia and, thus, the clinical syn-
dromes of defective glucose counterregu-
lation and hypoglycemia unawareness,
the components of hypoglycemia-
associated autonomic failure in diabetes
(24).
Predominant -cell regulation of
-cell glucagon secretion may also be rel-
evant to the pathogenesis of postprandial
as well as postabsorptive hyperglycemia
in type 1 diabetes and in type 2 diabetes
(14) if failure of postprandial suppression
of glucagon plays an important role (25).
Oral glucose tolerance tests in individuals
with normal glucose tolerance, impaired
glucose tolerance, and type 2 diabetes
documented an inverse relationship be-
tween the suppression of plasma gluca-
gon and plasma glucose concentrations
(25).Giventhepresentﬁndings,itiscon-
ceivable that diminished early -cell se-
cretion accounted for both progressively
increased plasma glucose concentrations
and progressively decreased suppression
of plasma glucagon concentrations with
progressive deterioration of glucose
tolerance.
In summary, these data indicate that,
among the array of signals, indirect recip-
rocal -cell–mediated signaling of -cells
predominates over direct -cell signaling
in the regulation of glucagon secretion in
humans.
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